History | Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | Guidance | NICE

History

Documents created during the development process.

Final draft guidance

Final draft guidance
Final appraisal document (PDF 292 KB)

Published:

14 July 2022
Committee papers (PDF 2.53 MB)

Published:

14 July 2022

Draft guidance: 1

Draft guidance: 1
Appraisal consultation document (PDF version) (PDF 356 KB)

Published:

27 August 2021
Appraisal consultation document (online commenting)
Public committee slides (PDF 1.83 MB)

Published:

27 August 2021
Committee papers (PDF 5.19 MB)

Published:

27 August 2021

Invitation to participate

Final scope (PDF 204 KB)

Published:

29 September 2020
Final stakeholder list (PDF 195 KB)

Published:

29 September 2020
Equality Impact Assessment (Guidance development) (PDF 156 KB)

Published:

29 September 2020
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 240 KB)

Published:

29 September 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 209 KB)

Published:

13 August 2020
Draft matrix post referral (PDF 192 KB)

Published:

13 August 2020

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 178 KB)

Published:

13 August 2019
Draft matrix post referral (PDF 191 KB)

Published:

13 August 2019